Fill in your contactinformation to download the whitepaper

Whitepaper consent
Newsletter consent

Fuel for bold innovators

Enabling the future of Healthcare and Life Sciences 

Creating the next generation of HealthTech ventures 

HERAN is enabling the next generation of healthcare and life sciences technology breakthroughs. 

As an active and engaged investor, we invest in great science, bold innovators and companies that aim to have transformative impact.

 

“Wind extinguishes a candle and energizes a fire”

We invest in teams that are tough, intelligent, perseverant and possess high levels of genuine positivity and an incredible drive to move things forward.

Discover our portfolio

With our expertise, network, guidance, and strong focus we aim to support those pioneers, disruptors and entrepreneurs who want and can improve healthcare in all its facets. We focus on innovation, technologies and science that can generate scalable positive impact and disruption within life sciences and healthcare. 

 logo
Invested:
2025
Country:
BE

Gynaia is a women’s health diagnostics company that empowers gynecological professionals with continuous learning, certification, and clinical-grade AI tools to improve care in gynecologic oncology, early pregnancy, obstetrics, fertility, and beyond. 
By combining explainable AI, regulatory-grade software, and a global expert network, Gynaia enables faster triage, earlier diagnoses, and fewer unnecessary procedures.

 logo
Invested:
2025
Country:
BE

Nuclivision develops software solutions for nuclear imaging, enhancing efficiency across the entire clinical workflow. Its mission is to support patients by improving the quality, safety, and accessibility of nuclear medicine. Their first product Nuclarity enables nuclear medicine physicians to perform PET scans with up to 50% less radioactivity and scan time.

 logo
Invested:
2023
Country:
BE

ImmuneSpec has developed a proprietary approach & process to conduct highly sensitive MAPPS assays, i.e., the analysis of MHC-associated peptide proteomics. This immunogenicity testing indicates whether a protein drug will result in a potential activation of the immune system. 

Who are we?

Heran Partners is a specialist venture capital investor committed to creating transformative impact within the life sciences and healthcare industry. We are a Belgium-based investment fund driven by a dedicated team with strong scientific and entrepreneurial backgrounds. We provide venture & growth capital accompanied by a strong network, expertise and mentorship to start-ups and scale-ups with a solid technology platform and strong market potential. 

News & insights

Thumb Team picture 2025

HERAN Investor Day 2025: How Heran fuels bold innovators in Healthcare and Life Sciences

On October 9th, 2025, we welcomed over 100 investors, founders and stakeholders to our annual Investor Day at De Koolputten in Waasmunster. The event reflected our investment philosophy: HERAN fuels bold innovators whose technologies are transforming healthcare and life sciences.

Read on
GEHC icometrix communication overview copy 1 0001 icometrix 03

HERAN and icometrix: A strategic partnership based on impact and trust

We are proud to announce the successful exit of icometrix, an AI leader in brain imaging now acquired by GE Healthcare. What began as early conviction in a promising idea grew into a global solution for neurology care. This journey reflects our approach: building long-term partnerships rooted in trust, strategic guidance and a commitment to impact.

Read on

Curious about what we
can do for you?

We’d love to hear your pitch!